Biotechnology company Complement Therapeutics (CTx) has formed a Clinical & Scientific Advisory Board to help accelerate the development of its pipeline of therapeutics targeting complement-mediated diseases. The company’s lead investigational product, CTx001, is a gene therapy for dry age-related macular degeneration/geographic atrophy, which is a leading cause of blindness. The company hopes to evaluate CTx001 […]
Menu ≡ ╳ 
